Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Active Biotech

- PMLiVE

Teva buys Allergan generics unit for $40.5bn

Will now drop its six-month pursuit of Mylan

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

Teva launches contraception Seasonique in European markets

Birth control option available in Austria, Italy, Poland and Slovakia

Roche Basel Switzerland

Roche planning ocrelizumab filings in early 2016

Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

- PMLiVE

Generic Copaxone launches in US

Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction

Teva Pharma logo

Teva drug shows promise in movement disorder

Deutetrabenazine could be the first US-approved drug for tardive dyskinesia 

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

Teva Pharma logo

Teva set for FDA verdict on reslizumab early next year

Ruling for severe asthma therapy Cinquil expected by March 2016

Teva Pharma logo

Teva updates MS campaign with new online resource

You Don’t Know Jack About MS website features documentaries and blogs

Teva Pharma logo

Teva hit with $1.2bn pay-for-delay fine

Federal Trade Commission continues its tough stance against generic blocking

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links